Monaghan Patrick Pio, Shrestha Anne, Barrett Emma, Absar Mohammed Shamim
Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
Department of Surgery, Manchester University NHS Foundation Trust, Manchester, UK.
BJS Open. 2024 Oct 29;8(6). doi: 10.1093/bjsopen/zrae138.
Breast cancer is the most common malignancy worldwide. The disease is more severe in younger women and often confers a poorer prognosis. This study aimed to profile a cohort of young women with breast cancer and address whether aspects of their tumour biology were related to their long-term outcomes.
The records of consecutive women aged 40 and under with a diagnosis of breast cancer at a single centre between 1 January 2010 and 30 December 2015 were analysed and a profile was created. They were followed up until 19 July 2023 (median 112 months, range 4-161), and the impact of oestrogen positivity (ER+), human epidermal growth factor 2 positivity (HER2+), tumour grade, axillary lymph node metastases and Ki67 value on overall survival and disease-free interval (DFI) was investigated.
One hundred and sixty-four patients were included. Younger patients typically presented with large, high-grade tumours with axillary lymph node metastases, and 83.2% of the cohort were alive at 5 years. ER+ tumours appeared to have a better 5-year survival: ER+/HER2- 86.3%, ER+/HER2+ 88.5%, ER-/HER2+ 71.4%, and triple-negative (ER-/HER2-) 70.8%. However, neither the log-rank test nor the Cox regression model found a significant effect of ER status and long-term survival (P = 0.485 and P = 0.158 respectively).
Young patients with breast cancer have a lower 5-year survival than the UK average for all ages, and patients in this single-centre study with ER+ tumours appeared to have better short-term but similar longer-term outcomes compared to ER- breast cancer.
乳腺癌是全球最常见的恶性肿瘤。该疾病在年轻女性中更为严重，且通常预后较差。本研究旨在描述一组年轻乳腺癌女性的特征，并探讨其肿瘤生物学方面是否与长期预后相关。
分析了2010年1月1日至2015年12月31日期间在单一中心确诊为乳腺癌的40岁及以下连续女性的记录，并创建了一份资料。对她们进行随访直至2023年7月19日（中位随访112个月，范围4 - 161个月），并研究雌激素阳性（ER +）、人表皮生长因子2阳性（HER2 +）、肿瘤分级、腋窝淋巴结转移和Ki67值对总生存期和无病间期（DFI）的影响。
纳入了164例患者。年轻患者通常表现为伴有腋窝淋巴结转移的大的高级别肿瘤，该队列中83.2%的患者在5年后仍存活。ER +肿瘤似乎有更好的5年生存率：ER + /HER2 -为86.3%，ER + /HER2 +为88.5%，ER - /HER2 +为71.4%，三阴性（ER - /HER2 -）为70.8%。然而，对数秩检验和Cox回归模型均未发现ER状态与长期生存之间有显著影响（分别为P = 0.485和P = 0.158）。
年轻乳腺癌患者的5年生存率低于英国所有年龄段的平均水平，在这项单中心研究中，与ER -乳腺癌相比，ER +肿瘤患者似乎有更好的短期预后，但长期预后相似。
